Celsion Corporation/$IMNN
Celsion shares are trading higher after the company announced positive data from its Phase 2 ovarian cancer study at ASCO.
9 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Celsion Corporation
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
Ticker
$IMNN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
25
ISIN
US15117N6022
Website
IMNN Metrics
BasicAdvanced
$31M
-
-$1.39
1.75
-
Price and volume
Market cap
$31M
Beta
1.75
52-week high
$3.16
52-week low
$0.37
Average daily volume
21M
Financial strength
Current ratio
0.878
Quick ratio
0.495
Long term debt to equity
135.649
Total debt to equity
223.006
Management effectiveness
Return on assets (TTM)
-107.77%
Return on equity (TTM)
-397.54%
Valuation
Price to book
45.28
Price to tangible book (TTM)
45.29
Price to free cash flow (TTM)
-1.112
Growth
Earnings per share change (TTM)
-31.23%
3-year earnings per share growth (CAGR)
-29.50%
IMNN News
AllArticlesVideos
IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study
GlobeNewsWire·4 days ago
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS
GlobeNewsWire·5 days ago
IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Celsion Corporation stock?
Celsion Corporation (IMNN) has a market cap of $31M as of June 07, 2025.
What is the P/E ratio for Celsion Corporation stock?
The price to earnings (P/E) ratio for Celsion Corporation (IMNN) stock is 0 as of June 07, 2025.
Does Celsion Corporation stock pay dividends?
No, Celsion Corporation (IMNN) stock does not pay dividends to its shareholders as of June 07, 2025.
When is the next Celsion Corporation dividend payment date?
Celsion Corporation (IMNN) stock does not pay dividends to its shareholders.
What is the beta indicator for Celsion Corporation?
Celsion Corporation (IMNN) has a beta rating of 1.75. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.